Ernexa Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.07 21:39
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.15.

EBIT: As of FY2025 Q3, the actual value is USD -1.265 M.

Segment Revenue

  • No revenue was generated for the three and nine months ended September 30, 2025, compared to $487,000 and $581,000 for the same periods in 2024, respectively.

Operational Metrics

  • Net Loss: The net loss for the three months ended September 30, 2025, was $1.2 million, a significant improvement from the $26.6 million loss in the same period in 2024. For the nine months ended September 30, 2025, the net loss was $12.6 million, compared to $38.8 million in 2024.
  • Operating Expenses: Total operating expenses decreased to $1.993 million for the three months ended September 30, 2025, from $2.806 million in 2024. For the nine months ended September 30, 2025, operating expenses were $7.225 million, down from $13.462 million in 2024.

Cash Flow

  • Operating Cash Flow: Net cash used in operating activities was $5.9 million for the nine months ended September 30, 2025, compared to $12.3 million in 2024.
  • Free Cash Flow: Not explicitly stated, but the net increase in cash and cash equivalents was $1.318 million for the nine months ended September 30, 2025, compared to a decrease of $7.406 million in 2024.

Unique Metrics

  • Forward Sales Contract Expense: A non-cash expense of $5.8 million was recognized in the nine months ended September 30, 2025, related to a forward sales contract.

Future Outlook and Strategy

  • Core Business Focus: Ernexa Therapeutics Inc. plans to complete IND enabling studies and submit an IND for ERNA-101 by 2026, with a Phase I clinical trial expected in the same year. The company is also investigating ERNA-201 for autoimmune disorders.
  • Non-Core Business: The company is seeking strategic partnerships to co-develop or out-license therapeutic assets and is applying for research grants to support its operations.
  • Priority: The company emphasizes the need to raise additional capital to fund operations beyond the next 12 months, with no current arrangements for capital in place.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.